Article Details

Roche to Study Syros' CDK7 Inhibitor With Tecentriq in BRAF-Mutated Colorectal Cancer Patients

Retrieved on: 2021-08-05 14:45:09

Tags for this article:

Click the tags to see associated articles and topics

Roche to Study Syros' CDK7 Inhibitor With Tecentriq in BRAF-Mutated Colorectal Cancer Patients. View article details on hiswai:

Excerpt

Roche's rationale for combining atezolizumab with a SY-5609 is backed by preclinical data showing that CDK7 inhibition leads to DNA replication stress ...

Article found on: www.precisiononcologynews.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up